Literature DB >> 7852486

Therapeutic controversies. Radioiodine may be bad for Graves' ophthalmopathy, but....

A Pinchera1, L Bartalena, C Marcocci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7852486     DOI： 10.1210/jcem.80.2.7852486

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  5 in total

Review 1.  An update on medical management of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; M L Tanda; E Piantanida; A Lai; M Marinò; A Pinchera
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

Review 2.  Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy?

Authors:  C Marcocci; L Bartalena; A Pinchera
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

3.  Subtotal thyroidectomy: a reliable method to achieve euthyroidism in Graves' disease. Prognostic factors.

Authors:  Pablo Moreno; José M Gómez; Núria Gómez; José M Francos; Emilio Ramos; Antonio Rafecas; E Jaurrieta
Journal:  World J Surg       Date:  2006-11       Impact factor: 3.352

Review 4.  Relationship between management of hyperthyroidism and course of the ophthalmopathy.

Authors:  L Bartalena; M L Tanda; E Piantanida; A Lai; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 5.  Role of thyroglobulin in the pathogenesis of Graves' ophthalmopathy: the hypothesis of Kriss revisited.

Authors:  M Marinò; L Chiovato; S Lisi; M A Altea; C Marcocci; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.